Contact us
 |
[email protected] |
 |
3275638434 |
 |
 |
| Paper Publishing WeChat |
Useful Links
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Article
Author(s)
Fabio Corsi, Luca Sorrentino, Serena Mazzucchelli, Marta Truffi, Amedeo Capetti, Giuliano Rizzardini and Luisa Fiandra
Full-Text PDF
XML 1005 Views
DOI:10.17265/2328-2150/2016.07.007
Affiliation(s)
ABSTRACT
In HIV-1 management, eradication of the virus from sanctuaries represents a major and challenging goal. The genital tract, gut associated lymphoid tissue, lymph nodes, central nervous system, macrophages and latently infected CD4+ T lymphocytes are typical sites where HIV-1 compartmentalizes. To circumvent this problem, a consistent number of studies have focused on improving ARVs (antiretroviral drugs) delivery into sanctuary sites and different nanotechnological approaches have been developed. Cellular HIV-1 sanctuaries (i.e. macrophages) can be reached by nanoformulation of ARVs or by activation of latently infected cells. Anatomical sanctuaries (i.e. brain or male genital tract) can be addressed by increasing the permeation of ARVs across tissue barriers, such as the blood-brain barrier or the blood-testis barrier, while ARVs concentration in lymph nodes can be enhanced by drug encapsulation in CD4-targeted nanoparticles.
KEYWORDS
Nanotechnology, HIV-1, antiretrovirals, sanctuaries, delivery.
Cite this paper
Corsi, F., et al. 2016. “Antiretroviral Therapy through Barriers: A Prominent Role for Nanotechnology in HIV-1 Eradication from Sanctuaries.” Journal of Pharmacy and Pharmacology 4 (7): 328-340.
References